Other Infections

AASLD 2017: Experimental NASH Therapy Improves Liver Fat and Fibrosis

GS-0976, an acetyl-CoA carboxylase (ACC) inhibitor being developed by Gilead Sciences, led to significant reductions in liver fat accumulation and fibrosis in people with non-alcoholic steatohepatitis (NASH), according to Phase 2 study results presented at the 2017 AASLD Liver Meeting last week in Washington, DC.

alt

Read more:

Cenicriviroc May Reduce Fibrosis in People with Fatty Liver Disease

Cenicriviroc, a drug that blocks both CCR5 and CCR2 receptors on immune cells, was associated with a decrease in liver fibrosis in people with non-alcoholic steatosis, a type of fatty liver disease, according to a report in the August 17 online edition of Hepatology.

alt

Read more:

EASL 2015: Milk Thistle May Improve Steatohepatitis, Capsaicin from Chili Peppers Helps Fibrosis

People who used silymarin, derived from the milk thistle plant, experienced a resolution of non-alcoholic steatohepatitis (NASH) and a reduction in liver fibrosis in a randomized, placebo-controlled trial, researchers reported at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna. Another study found that dietary capsaicin, derived from chili peppers, was associated with improvement in mice with artificially induced fibrosis, the precursor to cirrhosis.

alt

Read more:

AASLD 2016: When You Eat May Contribute to Fatty Liver Disease as Much as What You Eat

People who skip breakfast and eat late at night may have an elevated risk of non-alcoholic fatty liver disease (NAFLD), according to research presented at the AASLD Liver Meeting this week in Boston. This suggests that meal timing and frequency of meals may be modifiable risk factors for fatty liver disease, which can lead to cirrhosis and liver cancer.

alt

Read more:

Ezetimibe Did Not Reduce Liver Fat in NASH Trial, New Therapies Under Study

Ezetimibe (Zetia) did not perform significantly better than placebo in reducing liver fat among people with non-alcoholic steatohepatitis (NASH), according to a report in the December 6 edition of Hepatology. In related news, the FDA has designated Tobira's cenicriviroc -- also active against HIV -- as a fast-track therapy for NASH and Gilead Sciences announced a partnership to enter the NASH arena.

alt

Read more:

AASLD 2015: Coffee Linked to Reduced Liver Fibrosis in People with HBV, HCV, and NAFLD

Drinking coffee was associated with lower liver stiffness -- a non-invasive measure used to estimate liver fibrosis -- in people with hepatitis B, hepatitis C, and non-alcoholic fatty liver disease (NAFLD), researchers reported at the 2015 AASLD Liver Meeting last week in San Francisco. The study also showed a trend toward less liver fat build-up in people with NAFLD.alt

Read more:

EASL 2014: Fatty Liver Disease Is a Risk Factor for Heart Disease and Diabetes

Non-alcoholic fatty liver disease is associated with increased risk of cardiovascular disease, as indicated by atherosclerosis of the carotid artery, according to a study presented at the 49thEASL International Liver Congress (EASL 2014) this week in London. A related study found that fatty liver is also associated with diabetes, and reduction of liver fat lowers diabetes risk.

alt

Read more: